Arizona Cancer Therapeutics

Arizona Cancer Therapeutics, LLC, is an early-stage biopharmaceutical company developing targeted peptide-based therapies for the treatment of cancer. Our lead drug EJ1 is a protein transduction domain-MUC1 inhibitory peptide (PMIP) for the treatment of breast cancer (preclinical). PMIP is an intracellular MUC1 peptide that acts as a decoy to block the MUC1- oncoprotein interactions that drive breast cancer growth and metastasis. This program is being developed in collaboration with University of Arizona Cancer Center

网站

https://www.arizonacancertherapeutics.com

Arizona Cancer Therapeutics的外部链接

所属行业

生物技术研究

规模

11-50 人

总部

Tucson，Arizona

类型

私人持股

创立

2013